Assoc. Prof. Dr. Christian Kowol
Prodrug Development, Drug Delivery Systems, Drug Targeting
Phone: +43 1 4277 52611
Email: christian.kowol@univie.ac.at
Währinger Straße 42, Room W2164
» CV
» Publications
» Teaching
Research Focus
Chemotherapy and therapy with small targeted molecules are two major strategies for treatment of human cancer at the disseminated stage. However, even when using new targeted drugs, the therapy is often limited by severe side effects, resistance development and insufficient tumor accumulation.
The research of my group focuses on the development of new strategies to overcome these limitations:
- Bioinorganic prodrug development of clinically approved drugs to prevent the occurrence of severe side effects
- Drug delivery systems like nanoparticles, liposomes, polymers for tumor-specific accumulation and activation of anticancer drugs
- Drug targeting strategies using tumor-specific peptides
All research projects are highly interdisciplinary and are developed in close cooperation with the Institute of Cancer Research of the Medical University of Vienna within the Research Cluster “Translational Cancer Therapy Research”.
News & Press Releases
- Nanocarrier: Minitransporter auf Tumorjagd
- "Altes in neuem Glanz: Platin in der Krebstherapie"
- New interdisciplinary Research Group for investigation of the tumor microenvironment
- "Chemical Reviews" article: Metal chemotherapy drugs boost the impact of immunotherapy in cancer
- Foundation of spin-off "P4 Therapeutics": The next generation of platinum drugs
Awards
2016 Förderpreis of the Vienna Fund for Innovative Interdisciplinary Cancer Research for the publication “Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation"
2014 INiTS Award, 1st place for “Tumor-specific, Hypoxia-based Activation of EGFR-Inhibitors”
2014 RIZ GENIUS Award, 3rd place for “Tumor-specific Tyrosinkinase Inhibitors for Efficient Cancer Therapy”
2011 Forschungsentwicklungspreis of the Vienna Fund for innovative interdisciplinary cancer research
2010 Bank Austria Award to support innovative research projects (Preis zur Förderung innovativer Forschungsprojekte)
Scientific Collaborations
KARST, Uwe, University of Münster, Germany
ENYEDY, Éva Anna, University of Szeged, Hungary
FALLER Peter, University of Strasbourg, France
TEASDALE, Ian, Johannes Kepler University Linz, Austria
Team
Dipl.-Ing. Marlene Mathuber
Metal-based Anticancer Prodrugs
Phone: +43 1 4277 52613
Email: marlene.mathuber@univie.ac.at
Währinger Straße 42, Room W2168
Philipp Fronik, MSc MSc
Metal-based Anticancer Prodrugs
Phone: +43 1 4277 52613
Email: philipp.fronik@univie.ac.at
Währinger Straße 42, Room W2168
Alexander Kastner, MSc
Metal-based Anticancer prodrugs
Email: alexander.kastner@univie.ac.at
Phone: +43 1 4277 52613
Währinger Straße 42, Room W2168
Martijn Dijkstra, MSc
Anticancer Platinum(IV) Prodrugs
Email: martijn.dijkstra@univie.ac.at
Währinger Straße 42, Room W2167
Anja Federa, BSc.
Anticancer tyrosine kinase inhibitor prodrugs
Währinger Straße 42, Room W2167
Alexander Unterlercher, BSc.
Anticancer thiosemicarbazone prodrug systems
Phone: +43 1 4277 52614
Währinger Straße 42, Room W2169
Björn Bielec, MSc.
Anticancer Prodrugs
Email: bjoern.bielec@univie.ac.at
Former Team Members
- Sebastian Kallus (PhD Student)
Drug delivery systems for cancer therapy - Karla Pelivan (PhD Student)
Bioanalytical investigations of thiosemicarbazone anticancer drugs - Marianne Lahnsteiner (Master's Student)
Synthesis and reactivity of thiol-targeting moieties for drug delivery - Florian Bachmann (Master's Student)
Novel albumin-targeting platinum anticancer complexes - Julia Nunes (Visiting PhD Student, Department of Inorganic Chemistry Department, University of Campinas (UNICAMP), Brazil)